#Aveo Pharmaceuticals Inc (AVEO)

Your Questions, Our Answers

Prohost Portfolio PLUS (formerly The Week in Review) Your Questions, Our Answers In the upcoming issues of Prohost Portfolio PLUS, as with all our Tables, we will include observations and target chang...

P

Prohost Biotech

Mar 28, 2021

A Flashback and Future Projections

Prohost Letter #445 A Flashback and Future Projections 1. A Follow-Up on Recently Posted News from ProhostBiotech 2. Answering Questions 3. Development-Stage Firms to Outperform 4. Oversold Revenue-Ge...

P

Prohost Biotech

Mar 24, 2021

1m

2

News & Comments

Aveo Oncology: The FDA Approved FOTIVDA for Adults with Relapsed or Refractory Advanced RCC

Aveo Oncology Received FDA Approval for FOTIVDA for Advanced RCC Aveo Oncology (AVEO) drug FOTIVDA is an oral, next-generation vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI)...

P

Prohost Biotech

Mar 11, 2021

Biotech News Not Related to the FED. Indeed We Have Good News

THE MARKET AND THE FED From Smitty: “Well we are here and in just a few hours we will hear from The Fed and within minutes after traders will react and then it’s back to reality. The real question rem...

P

Prohost Biotech

Jun 19, 2013

The AVEO Verdict and Other Firms' Triumphs. Read Also About Gilead

Unemployment and the economy in general are much better than analysts’ expectations. Biotechnology is in its best shape ever. This is excellent news about the economy to begin the day and the month...

P

Prohost Biotech

May 3, 2013

AVEO: A Premature Selloff

A selloff in Aveo’s (AVEO) occurred today, as the FDA asked the panel whether the company should conduct another trial for its kidney cancer drug tivozanib to assess the benefit? Aveo’s Tivozanib woul...

P

Prohost Biotech

Apr 30, 2013

Will Aveo's Drug Tivozanib Be Approved? Read Also About LIFE and GILD

Life Technologies LIFE) Reuters reported that Thermo Fisher Scientific (TMO), the world’s largest maker of laboratory equipment and scientific instruments, had held discussions with Life Technolog...

P

Prohost Biotech

Feb 21, 2013

Today's News Features AVEO, SQNM and ALNY. We Comment on Newly Introduced Non-Invasive Prenatal Testing, an Instigational Kidney Cancer Drug and a New Agreement for Alnylam

AVEO PHARMACEUTICALS (AVEO) Aveo Proving its Point On January 29, 2013, Aveo Pharmaceuticals (AVEO) announced it will present updated data on its kidney cancer drug tivozanib . The update will fo...

P

Prohost Biotech

Feb 4, 2013

We Need to Know Why Ariad's Stock Experienced a Selloff in Early Morning Trading. Also Read Aveo's News, Alimera's Approval and Elan's Tysabri

TODAY’S N EW S ARIAD (ARIA) What happened to Ariad’s stock in early trading did not go unnoticed, but remained without explanation. An unexplained sudden drop of nearly $1 in the stock price in ear...

P

Prohost Biotech

Jan 18, 2013

The End of the Road Towards Approval of Oncology Products and Other News about STEM, OSIR, and ACHN

ARIAD Completes Rolling Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration ARIAD (ARIA): Completed the rolling submission of the New Drug Application (NDA) for...

P

Prohost Biotech

Sep 28, 2012

The Impact of a Study Rallying Stocks. See Also: ALNY, ISIS, SRPT, SGMO, PCYC and PSTI

Taking Notes… What’s going on now with the biotechnology sector is not strange, new, or significant, except for a few biotech stocks that are consistently moving perpendicularly higher, reaching to w...

P

Prohost Biotech

Sep 17, 2012

1m

2

News & Comments

Why a Selloff in the Best of the Best Oncology Biotech Firms?

If the selloff of the best of the best small oncology biotech stocks was not a concerted, multiparty effort by influential groups, then what else could have caused it? The stocks devastated after the...

P

Prohost Biotech

Aug 15, 2012

The Most Promising, Most Undervalued Oncology Biotechs

IMMUNOGEN (IMGN) ImmunoGen (IMGN) has superior scientific, technological and pipeline products’ that are yet to be recognized by Wall Street. Its Targeted Antibody Payload (TAP) technology is sophist...

P

Prohost Biotech

Aug 3, 2012

The Crazy Season of Quarterly Biotech Financial Results

THE SEASON OF FINANCIAL RESULTS A season For Analysts Uncontrolled Caprice The automatic slashing of biotech stocks following the announcement of quarterly financial results continues as usual. The st...

P

Prohost Biotech

Aug 2, 2012

Good Financial Results, Approval Dates, Upgrades and One Table

7/25/2012 Joyful N E W S About Financial Results REGENERON The question we are being asked almost everyday and could not answer is: Why Regeneron Pharmaceuticals (REGN does not split its stock 5...

P

Prohost Biotech

Jul 25, 2012

A Glipmse at the Future: QGEN, AVEO, THLD and More

A glimpse at the future therapeutics was made possible, reading The New York Times' two articles written by Gina Kolada last Sunday and Monday. On Wednesday morning, we will post an article that demon...

P

Prohost Biotech

Jul 10, 2012

1m

0

News & Comments

Aveo and Exelixis at the Finish Line

News announcing that small biotech firms are filing for approval of breakthrough drugs targeting deadly diseases is worth admiration, not cynicism. Humans look for miracles; yet, they impassively over...

P

Prohost Biotech

May 31, 2012

Vertex's Selling Nonsense, New Picks and Sequenom

This week’s bearish and bullish analysts will focus on ASCO . The difference, though, is that positive analysts will highlight firms that have promising products, while most negative analysts will de...

P

Prohost Biotech

May 29, 2012

In the Spotlight

Again, stock movements are weird and do not seem to follow any rational evaluation of companies. Instead, the oscillations are based on automatic buying and selling of stocks by daily traders. They bu...

P

Prohost Biotech

Feb 24, 2012

1m

0